AstraZeneca PLC (AZN) - Total Liabilities
Based on the latest financial reports, AstraZeneca PLC (AZN) has total liabilities worth $66.63 Billion USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
AstraZeneca PLC - Total Liabilities Trend (1990–2025)
This chart illustrates how AstraZeneca PLC's total liabilities have evolved over time, based on quarterly financial data. See AZN current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
AstraZeneca PLC Competitors by Total Liabilities
The table below lists competitors of AstraZeneca PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Novartis AG
MX:NVSN
|
Mexico | MX$79.61 Billion |
|
Merck & Company Inc
NYSE:MRK
|
USA | $82.75 Billion |
|
Philip Morris International Inc
NYSE:PM
|
USA | $76.21 Billion |
|
Royal Bank of Canada
TO:RY
|
Canada | CA$2.19 Trillion |
|
Novartis AG ADR
NYSE:NVS
|
USA | $79.61 Billion |
|
AstraZeneca PLC
NYSE:AZN
|
USA | $66.63 Billion |
|
GE Vernova LLC
NYSE:GEV
|
USA | $60.55 Billion |
|
Contemporary Amperex Technology Co Ltd Class A
SHE:300750
|
China | CN¥652.10 Billion |
Liability Composition Analysis (1990–2025)
This chart breaks down AstraZeneca PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see AstraZeneca PLC (AZN) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.91 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.41 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how AstraZeneca PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for AstraZeneca PLC (1990–2025)
The table below shows the annual total liabilities of AstraZeneca PLC from 1990 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $65.36 Billion | +3.47% |
| 2024-12-31 | $63.16 Billion | +1.95% |
| 2023-12-31 | $61.95 Billion | +4.25% |
| 2022-12-31 | $59.42 Billion | -10.07% |
| 2021-12-31 | $66.08 Billion | +29.33% |
| 2020-12-31 | $51.09 Billion | +9.21% |
| 2019-12-31 | $46.78 Billion | +0.37% |
| 2018-12-31 | $46.61 Billion | -0.22% |
| 2017-12-31 | $46.71 Billion | +1.86% |
| 2016-12-31 | $45.86 Billion | +10.19% |
| 2015-12-31 | $41.62 Billion | +6.84% |
| 2014-12-31 | $38.95 Billion | +19.31% |
| 2013-12-31 | $32.65 Billion | +10.36% |
| 2012-12-31 | $29.58 Billion | +0.76% |
| 2011-12-31 | $29.36 Billion | -10.27% |
| 2010-12-31 | $32.72 Billion | -4.05% |
| 2009-12-31 | $34.10 Billion | +10.39% |
| 2008-12-31 | $30.89 Billion | -6.51% |
| 2007-12-31 | $33.04 Billion | +127.62% |
| 2006-12-31 | $14.52 Billion | +30.20% |
| 2005-12-31 | $11.15 Billion | -0.05% |
| 2004-12-31 | $11.15 Billion | +8.13% |
| 2003-12-31 | $10.32 Billion | -0.33% |
| 2002-12-31 | $10.35 Billion | -18.39% |
| 2001-12-31 | $12.68 Billion | +42.54% |
| 2000-12-31 | $8.90 Billion | -6.04% |
| 1999-12-31 | $9.47 Billion | +99.19% |
| 1998-12-31 | $4.75 Billion | +2.05% |
| 1997-12-31 | $4.66 Billion | -4.95% |
| 1996-12-31 | $4.90 Billion | +1.40% |
| 1995-12-31 | $4.83 Billion | +5.23% |
| 1994-12-31 | $4.59 Billion | -9.94% |
| 1993-12-31 | $5.10 Billion | -15.25% |
| 1992-12-31 | $6.02 Billion | +10.52% |
| 1991-12-31 | $5.45 Billion | +0.49% |
| 1990-12-31 | $5.42 Billion | -- |
About AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splend… Read more